Navigation Links
Sequella Lead Drug Compound SQ109 Selected for Phase 1B Clinical Trial Program
Date:1/6/2009

ROCKVILLE, Md., Jan. 6 /PRNewswire-USNewswire/ -- Sequella, Inc., a clinical-stage biopharmaceutical company focused on diseases of epidemic potential, announced today that SQ109, its lead drug candidate for the treatment of tuberculosis (TB), was the first drug approved for evaluation in a newly awarded clinical program contract to Dynport Vaccine Company LLC and Quintiles Transnational. The contract, awarded by the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), is part of NIAID's clinical resource infrastructure to accelerate Phase 1 studies of promising clinical stage drugs or vaccines that address emerging and re-emerging infectious tropical diseases and bioweapon pathogens. The Phase 1B clinical study of SQ109 should be initiated in Q1 2009.

SQ-109 is a new diamine antibiotic intended to replace one or more of the current first-line anti-TB drugs and simplify patient therapy. SQ109 was granted U.S. FDA Fast Track designation and FDA/EMEA Orphan Drug Designation in 2007. SQ109 shows activity against drug sensitive and multi-drug resistant (MDR and XDR) Mycobacterium tuberculosis, the causative agent of TB. The Phase 1B study will assess safety and pharmacokinetics of multiple doses of SQ109 in healthy subjects.

"This is absolutely the best of both worlds for Sequella," commented Dr. Carol Nacy, Sequella CEO. "We again successfully competed for support from our most valued funding partner, NIAID, while retaining the capacity to work with the same industry-leading contract research organization, Quintiles Transnational, that conducted our first-in-human Phase 1A trial for SQ109.

The trial will be conducted at the Overland Park Quintiles Transnational Phase 1 facility in Lenexa, Kansas.

About Sequella

Sequella is a clinical stage biopharmaceutical company focused on commercializing improved treatments for diseases of epidemic pot
'/>"/>

SOURCE Sequella, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Sequella Presents Data on Synergy Between Investigational New TB Drugs SQ109 and TMC207
2. Tibotec Data Presented at ICAAC and HIV9 Follow Key Regulatory Approvals for Anti-HIV Compounds
3. Portola Announces Data Presentations Relevant to Its Lead Phase II Antithrombotic Compounds at American Heart Association Scientific Sessions 2008
4. Lilly Announces Initiation of Second Global Phase III Trial of Investigational Alzheimers Disease Compound
5. Quigley Anti-Viral Compound QR448(a) Successfully Prevents Transmission of Infectious Bronchitis in Chickens
6. Novel Compound Shows Promise for Treatment of Alcoholism
7. Volcanos VH(R) IVUS Technology Used in Imaging Study of GlaxoSmithKlines Novel Investigational Compound, Darapladib
8. AstraZeneca Announces Innovative New Partnership With Singapore Institutions to Develop Anti-Cancer Compounds
9. Lixte Biotechnology Holdings Announces Filing of a New Patent Application for the Use of Novel Compounds as Potential Treatment for Neurodegenerative Diseases
10. Lixte Biotechnology Holdings Announces That Novel Compounds Being Developed as Potential Treatments for Brain Tumors Have Positive Activity in a Mouse Model of Human Pancreatic Cancer
11. HUYA Bioscience Intl Announces Pre-IND Outcome for HBI-3000 - Promising Anti-Arrhythmia Compound Sourced From China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... July 28, 2015 Amgen (NASDAQ: AMGN ... a $0.79 per share dividend for the third quarter ... 8, 2015, to all stockholders of record as of ... About Amgen Amgen is committed to unlocking ... illnesses by discovering, developing, manufacturing and delivering innovative human ...
(Date:7/28/2015)... July 28, 2015   Heska Corporation  (NASDAQ: ... provider of  advanced veterinary diagnostic and other specialty ... the new Element i ® Immunodiagnostic Analyzer. ... for key health concerns, including thyroid disorders, Cushing,s ... a compact bench top analyzer that delivers rapid ...
(Date:7/28/2015)... LOUIS, July 28, 2015  Express Scripts Holding Company ... income attributable to Express Scripts stockholders of $600.1 million, ... share, as detailed in Table 4, were $1.44 for ... is clear many companies across healthcare are validating the ... and Chief Executive Officer. "But, what matters most is ...
Breaking Medicine Technology:Amgen Announces 2015 Third Quarter Dividend 2Amgen Announces 2015 Third Quarter Dividend 3Heska Announces Veterinary Market's first and only point of care Analyzer for TSH, Total T4, and Cortisol results in minutes 2Heska Announces Veterinary Market's first and only point of care Analyzer for TSH, Total T4, and Cortisol results in minutes 3Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 2Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 3Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 4Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 5Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 6Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 7Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 8Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 9Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 10Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 11Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 12Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 13Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 14Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 15Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 16Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 17Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 18Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 19Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 20Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 21Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 22Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 23Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 24Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 25
... FRANCISCO, Calif., Feb. 3 Rigel,Pharmaceuticals, Inc. (Nasdaq: ... will delay,further partnership discussions regarding R788 until after ... are available. The company expects that,these ... the understanding of R788,s potential and may therefore,drive ...
... Feb. 2 Adolescents and young adults who ... than non-users to have disrupted brain development, according ... in areas of the brain that interconnect brain ... executive functioning skills. The findings are of particular ...
Cached Medicine Technology:Rigel Expects R788 Partnership After Phase 2b Clinical Trials Results 2Rigel Expects R788 Partnership After Phase 2b Clinical Trials Results 3Rigel Expects R788 Partnership After Phase 2b Clinical Trials Results 4Rigel Expects R788 Partnership After Phase 2b Clinical Trials Results 5Heavy Marijuana Use May Damage Developing Brain in Teens, Young Adults 2Heavy Marijuana Use May Damage Developing Brain in Teens, Young Adults 3
(Date:7/28/2015)... ... July 28, 2015 , ... A ... outcomes for inmates who continued methadone maintenance treatment (MMT) during incarceration versus those ... to relapse to opiate use (1) and more likely to require hospitalization or ...
(Date:7/28/2015)... ... July 28, 2015 , ... Morristown Medical Center, part of Atlantic Health ... the first five hospitals in the nation, to implant the newly approved CoreValve® Evolut® ... and all are in good condition. , The CoreValve® Evolut® R System was approved ...
(Date:7/28/2015)... ... ... Healthline , a provider of intelligent health information and technology solutions, ... digital health . The survey, which was conducted among 3,679 Healthline.com ... of trust in the security of digital health tools, impact of these tools on ...
(Date:7/28/2015)... ... July 28, 2015 , ... Dr. Aziz Ahmad recently gave a ... place from noon to 1 p.m. Tuesday, June 23, at the Gulf Coast Regional ... Dr. Ahmad is board-certified in colorectal surgery and has more than 35 years of ...
(Date:7/28/2015)... (PRWEB) , ... July 28, 2015 , ... According to ... able to stop the cycle of addiction in lab mice. The study involving isradipine ... for the new prospect of helping their clients overcome drug and alcohol addictions. The ...
Breaking Medicine News(10 mins):Health News:Novus Medical Detox Center Analyzes Methadone Study Findings and Implications for Opiate Abuse Treatment 2Health News:Novus Medical Detox Center Analyzes Methadone Study Findings and Implications for Opiate Abuse Treatment 3Health News:Novus Medical Detox Center Analyzes Methadone Study Findings and Implications for Opiate Abuse Treatment 4Health News:Morristown Medical Center First Hospital in New Jersey to Implant Newly Approved Heart Valve 2Health News:Morristown Medical Center First Hospital in New Jersey to Implant Newly Approved Heart Valve 3Health News:Consumers Concerned About Privacy of Personal Health Data on Wearables and Mobile Apps, According to New Healthline Survey 2Health News:Consumers Concerned About Privacy of Personal Health Data on Wearables and Mobile Apps, According to New Healthline Survey 3Health News:Consumers Concerned About Privacy of Personal Health Data on Wearables and Mobile Apps, According to New Healthline Survey 4Health News:Consumers Concerned About Privacy of Personal Health Data on Wearables and Mobile Apps, According to New Healthline Survey 5Health News:Dr. Aziz Ahmad Delivers Talk at Gulf Coast Medical Center 2Health News:Blood Pressure Medication May be the Key to Treating Addiction 2Health News:Blood Pressure Medication May be the Key to Treating Addiction 3
... been found that a herbal supplement can effectively combat cocaine ... a potential agent to modulate the effects of cocaine addiction.// ... treatment of heroin addiction, and possibly alcoholism. ,NAC ... for its antioxidant effects. Antioxidants are agents that clean up ...
... Huang and his team from Gladstone Institute of Neurological ... is responsible for causing Alzheimer's disease //that acts by ... cells due to the protein fragments released from apoE. ... responsible for causing Alzheimer’s disease by not providing the ...
... Ontario’s hospitals are getting longer, according to Government data which ... the Conservative health critic.// The waiting time rose from 34 ... cancer surgery, while it rose from 139 days to 142 ... days for cardiac surgeries, while in the case of angioplasty, ...
... levels of lead in soil and sediments left behind ... heightened health threat to returning residents, especially children, says ... from the area, lead levels were as much as ... considers safe, according to researchers at Texas Tech University. ...
... Failure of Democratic Nation Building: Ideology Meets Evolution' Dr. Steven ... or cannot be forcibly thrusted on a nation. ... hierarchical and authoritarian social and political // structures. ... before it is accepted by the people. ,It ...
... the Rockefeller University revealed that good taste is not an ... conducted on C.elagans which is a very simple nematode. It ... harmless and pathogenic ones).It has 302 neurons totally which can ... for the nervous system to function are very similar to ...
Cached Medicine News:Health News:A herbal drug addiction releiver 2Health News:Lead levels in disturbed soil post-Katrina unsafe 2Health News:Lead levels in disturbed soil post-Katrina unsafe 3Health News:Worms Learn To Choose Their Diet 2
An easy-to-fit high water content spherical soft lens manufactured using cast molding technology, and designed for use in the correction of myopia on a daily wear or extended wear basis....
... reflection mirrors to measure the position ... tumor removal or thyroid decompression. It ... is easy to handle- with a ... plastic mounts that are placed firmly ...
Fastest, easiest and least expensive method for measuring exophthalmos. By sighting at right angles, this device eliminates parallax and allows the clinician to measure the amount of protrusion or bu...
PLX40s, 40 Watt Sealed CO2 Laser System....
Medicine Products: